Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective Randomized Open-label Interventional Study to Investigate the Efficacy of Complement C5 Inhibition With Zilucoplan® in Improving Oxygenation and Short-and Longterm Outcome of COVID19 Patients With Acute Hypoxic Respiratory Failure

Next Previous
Search
Trial Profile

A Prospective Randomized Open-label Interventional Study to Investigate the Efficacy of Complement C5 Inhibition With Zilucoplan® in Improving Oxygenation and Short-and Longterm Outcome of COVID19 Patients With Acute Hypoxic Respiratory Failure

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 18 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zilucoplan (Primary)
  • Indications Acute hypoxia; COVID 2019 infections; Respiratory insufficiency
  • Focus Therapeutic Use
  • Acronyms ZILU-COV

Most Recent Events

  • 01 Jul 2021 Status changed from active, no longer recruiting to completed.
  • 01 Mar 2021 Planned End Date changed from 1 Apr 2021 to 30 Apr 2021.
  • 18 Dec 2020 Planned End Date changed from 1 Sep 2021 to 1 Apr 2021.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top